- DiaMedica Therapeutics press release ( NASDAQ: DMAC ): Q3 GAAP EPS of -$0.12 beats by $0.03 .
- Total cash, cash equivalents and investments of $36.1M.
For further details see:
DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03For further details see:
DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
Market:
DiaMedica Therapeutics Inc. Website:
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. Th...